L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics

Asthma Clinical Trial

— SANDIA  

Official title:

L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01715844
• Other study ID #: L-citrulline Asthma
• Status: Completed
• Phase: Phase 1
• First received: October 16, 2012
• Last updated: June 29, 2017
• Start date: September 7, 2013
• Est. completion date: June 1, 2017

Study information

• Verified date: June 2017
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In people who develop asthma after the age of 12 and who are also overweigh, there can be an increased burden of asthma symptoms, more flare-ups, and poorly-controlled asthma when compared to normal weight asthmatics. Certain factors are more abundant in the blood of individuals who are obese. One such factor is derived from the metabolism of an amino acid found in your diet, which is known as L-arginine (Amino acids are most commonly known as the building blocks of proteins, the same as the proteins found in food). This factor is called asymmetric dimethylarginine or ADMA. The balance of L-arginine to ADMA may be important to the health of subjects with asthma. The balance between L-arginine and ADMA plays an important role in producing nitric oxide (NO) in the airways. NO is normally produced in the lung and plays a major role in maintaining airways open and functioning normally. Our research has shown that in subjects with asthma who are overweight and developed asthma later in life, the combination of low L-arginine and high ADMA, may lead to lower NO levels. We are asking participants in this study to take L-citrulline, which is converted to L-arginine by your body, as a supplement for a period of one week. We anticipate that L-citrulline will restore NO levels in the airways, by increasing the ratio of L-arginine to ADMA

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 1, 2017
• Est. primary completion date: June 1, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and female patients, 18-75 yrs old, from all racial/ethnic backgrounds

• Diagnosis of asthma for >1 yr

• BMI = 30

• Baseline pre-bronchodilator FEV1 between 60 and 90% predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol

• Smoking history <20 pack years and no smoking in the last year

• Able to identify age of asthma onset

Exclusion Criteria:

• Respiratory tract infection within the last 4 weeks;

• Oral CS burst within the last 4 weeks or regular systemic CS use

• Hospitalization within the last 3 months

• ER visit within the 4 weeks

• Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes

• Current smoking or within the previous 12 months

• Current use of statins for the past 30 days (Statins lower ADMA levels)

• Pregnancy

• Intolerance or allergy to L-arginine or L-citrulline

• Phosphodiesterase inhibitors

• Taking oral nitrates

Related Conditions & MeSH terms

• Asthma
• Overweight

Intervention

Dietary Supplement:
• L-citrulline
Patients will take 3-gr of L-citrulline/day for 7 days

Locations

Country	Name	City	State
United States	Asthma Institute, University of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Exhaled nitric oxide	Patients will be randomized to 1 week of 3 g of L-citrulline/day vs matching placebo, The outcome is the pre to post intervention change in exhaled NO	1 week
Secondary	Sputum and plasma L-arginine/ADMA levels	This outcome compares the pre to post L-citrulline supplementation changes in sputum and plasma L-arginine/ADMA	1 week